NSW pharmacists to treat skin conditions

 

Pharmacists in New South Wales will soon be able to supply treatment for four skin conditions under the next phase of the NSW Pharmacy Trial.

Participating NSW pharmacists who undertake additional training will be able to treat impetigo, shingles, atopic dermatitis, and mild plaque psoriasis under the trial.

Pharmaceutical Society of Australia (PSA) New South Wales President Luke Kelly FPS welcomed the next phase of the NSW Pharmacy Trial, and reaffirmed PSA’s support for pharmacists participating in the program.

“Under the next phase of the New South Wales Pharmacy Trial community pharmacists will be trained to treat four skin conditions, making treatment for conditions including impetigo, shingles, eczema, and mild plaque psoriasis more accessible around our state,” Mr Kelly said.

“Pharmacists are key to strengthening the healthcare system, and through the NSW Pharmacy Trial, patients have been able to access safe, quality treatment when and where they need it.

“For skin conditions like shingles, acute eczema, mild plaque psoriasis and impetigo, providing timely, accessible treatment is critical to relieving discomfort and pain, and allow us to mitigate further complications.

“New South Wales pharmacists have already supported thousands of patients with a range of health concerns, including uncomplicated Urinary Tract Infections and extending the supply of the oral contraceptive pill. With the inclusion of skin conditions, pharmacists can continue to provide nation-leading, accessible care to patients across the state.

Mr Kelly also welcomed increased remuneration for pharmacists providing consultations skin conditions, better reflecting clinical expertise and administration costs.

“Increased support for pharmacists means we can ensure services remain available to patients across our state, at no cost.

“We look forward to continuing to work closely with Minister Park, the New South Wales Government and other stakeholders to ensure we are best responding to the health needs of our communities,” Mr Kelly said.

 

TAGS: NSW, pharmacist, skin conditions, trial expansion, community pharmacy, scope of practice.

Must Read

New guidelines for the management of POI

0
The 2024 guidelines on diagnosing and managing premature ovarian insufficiency (POI) have been released, marking a significant advancement in women's health. Developed by the Centre...